EMERGENT BIOSOLUTIONS INC. lobbying for EMERGENT BIOSOLUTIONS INC

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 16, 2026

Expenses

$430,000.00

What this organization spent lobbying with its own staff. Reported using C: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 5

Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Office of Natl Drug Control Policy (NDCP)
SENATE
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 3

HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
HR 2483
SUPPORT for Patients and Communities Reauthorization Act of 2025
HR 5252
HOPE Act

Lobbying activity 4

Homeland Security

- Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield forFY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act

Disaster Planning/Emergencies

- Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield forFY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act

Budget/Appropriations

- Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield forFY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act

Health Issues

- Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield forFY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act